235results about How to "Increase lethality" patented technology

The invention belongs to the technical field of metal organic frameworks, and particularly relates to a high-performance photocatalytic metal organic framework antibacterial material as well as a preparation method and application thereof. The preparation method comprises the following steps of: growing a metal organic framework UiO 66 which takes a cerium element as a metal node on a single-layer graphene oxide UiO66 (at) GO in situ, loading arginine small molecules in the MOF framework to obtain a high-performance photocatalytic MOF antibacterial material UiO66 (at) GO (at) arg, forming a nano hydrogel with a stable three-dimensional structure with chitosan, and performing antibacterial treatment by using the nano hydrogel as a wound dressing. The Ce-based MOF composite QCS / GO-UiO 66-coated arg / PNIPAm hydrogel prepared by the preparation method disclosed by the invention has excellent properties such as elasticity, adhesive power, water absorption and biocompatibility; and under illumination, the photocatalyst has an excellent photocatalytic sterilization effect, and has a good killing effect on escherichia coli and staphylococcus aureus.

The invention provides a compound DOTA-HX2-DZ and application thereof, and belongs to the technical field of biological medicine. According to the invention, the molecular structure of DZ-HX2-DOTA is optimized, and a special connexon is designed and adopted, so that the problem of limited anti-tumor curative effect caused by poorer stability, fat solubility, tumor residence time and other properties of a radiolabeled drug in the prior art is solved. The compound provided by the invention can significantly reduce the risk of label removal of radioactive metal ions in an in-vivo environment, and ensures that the compound stably plays a role at a targeted part; the compound has excellent molecular lipid solubility, can penetrate cell membranes and vascular barriers more easily, improves the bioavailability of drugs, prolongs the in-vivo circulation time, prolongs the tumor residence time, and further improves the treatment efficiency. The DZ-HX2-DOTA disclosed by the invention has broad-spectrum tumor targeting property, and can be used for diagnosing and treating various types of malignant tumors.

The invention provides a preparation method and application of a high-efficiency encapsulated pH-responsive drug-loaded liposome. According to the method, two-phase fluid of a medicine aqueous solution and a lipid component organic solution in a micro-channel is accurately controlled, and the efficiently encapsulated liposome is prepared from bottom to top by utilizing a micro-mixing technology. Compared with a conventional passive drug loading method which is relatively low in encapsulation efficiency in preparation of hydrophilic drug nano-liposomes, the method provided by the invention can improve the encapsulation efficiency to be close to 95% under optimized prescription and process conditions. According to the invention, by adjusting the proportion of each component in the prescription and the preparation process, the release behavior of liposome drugs such as adriamycin and the like can be adjusted, and the drug release shows pH responsiveness. Through efficient encapsulation of adriamycin and the like and pH-responsive release of the liposome dosage form, the effects of efficacy enhancement and toxicity reduction are achieved in the anti-tumor treatment aspect.

The invention belongs to the technical field of medicines, and particularly discloses application of moss phenol glucoside in preparation of medicines for preventing and / or treating tumors. According to the method, activated CD8 + T cells, MC38-OVA cells and traditional Chinese medicine monomeric compounds are co-cultured, the traditional Chinese medicine monomeric compounds capable of effectively promoting the anti-tumor activity of the CD8 + T cells are selected by utilizing a high-content screening technology, and finally, the experiment is carried out by taking the moss phenol glucoside as a research object. In-vitro experiment results show that the moss phenol glucoside can significantly promote T cell activation, promote release of cell factors such as IFN-gamma and TNF-alpha, and enhance the killing effect of T cells on tumors. A mouse in-vivo tumor-bearing experiment result shows that the moss phenol glucoside can promote the anti-tumor activity of T cells so as to inhibit tumor growth, has no obvious toxic or side effect, can be used for preparing the medicine for preventing and / or treating tumors, and has a potential clinical application prospect and a relatively high economic value.

The invention discloses stenotrophomonas maltophilia bacteriophage, a composition and application thereof. Relates to the technical field of biology, the stenotrophomonas maltophilia bacteriophage comprises a bacteriophage vBSma-SZP9, the taxonomic name of the bacteriophage vBSma-SZP9 is Snotrophomonas phage, the Latin literature name of the bacteriophage vBSma-SZP9 is Snotrophomonas phage, the bacteriophage vBSma-SZP9 is preserved in the Guangdong Microbiological Culture Collection Center, the preservation address is the fifth floor of the building 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No: 64509-B1, and the preservation date is May 16, 2024. The bacteriophage disclosed by the invention is wide in host spectrum, strong in infection ability and wide in temperature and acid-base tolerance range.

The invention provides a preparation method of a PSR.Syn.CD19. CD38 CAR-T cell as well as the cell and application of the PSR.Syn.CD19. CD38 CAR-T cell, the PSR.Syn.CD19. CD38 CAR-T cell is characterized in that after the CAR-T cell and a CD19 antigen positive tumor cell are co-incubated, effector molecule anti-CD38-CAR can be induced to express, and when the tumor cell simultaneously expresses CD19 and CD38 antigens, the CAR-T cell capable of recognizing and killing tumors can be identified. The CAR-T cell provided by the invention can efficiently and specifically kill tumor cells (CD19 + CD38 +), has a persistent killing effect, and has a safety switch capable of starting a killing function. Besides, the tumor can be specifically killed, the cell proliferation rate is high, the anti-tumor function can be improved through a large amount of secreted IL-2, IFN-gamma, TNF-alpha and Granzyme B, and the application safety of the cell is greatly improved.

The invention provides a Chinese herbal medicine composition for improving immunity as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: fermenting rhizoma anemarrhenae, poria cocos, rhizoma polygonati and fructus lycii to prepare Chinese herbal medicine selenium / germanium-rich polysaccharide, carrying out carboxylation modification on the Chinese herbal medicine selenium / germanium-rich polysaccharide and phycobiliprotein to prepare a Chinese herbal medicine selenium / germanium-rich polysaccharide-phycobiliprotein compound, and dissolving bacterial sludge in the fermentation process with helicase to prepare a bacteria-dissolving product; and uniformly stirring and mixing with the Chinese herbal medicine selenium / germanium-rich polysaccharide-phycobiliprotein compound, berberine and camptothecin to prepare the Chinese herbal medicine composition for improving immunity. The prepared Chinese herbal medicine composition capable of improving immunity contains rich glycoprotein and organic selenium / germanium compounds, has the effects of consolidating body resistance and strengthening yang, has the advantages of good sterilization, oxidation resistance, inflammation resistance, virus resistance and tumor resistance, no toxicity, high bioavailability, easiness in absorption and the like, is high in patient compliance and has a wide application prospect.

The invention relates to a preparation method of CAR-T cells and a product thereof. A method for preparing a CAR-T cell according to the present invention comprises the step of introducing a cyclic mRNA into a T cell that does not contain a chimeric antigen receptor; and, the cyclic mRNA comprises a first cyclic mRNA encoding a chimeric antigen receptor; in addition, the first annular mRNA comprises the following sequence (a) or (b): (a) a translation starting sequence and a coding sequence; and (b) translating the starting sequence, the coding sequence and the insertion element sequence. In the method, the transfection efficiency of the annular mRNA is high, and the positive rate is as high as 90%; compared with preparation methods of viruses, transposon systems and the like, the process is simple, the production cost is greatly reduced, and the safety is also improved; compared with linear mRNA, the protein expression time is greatly prolonged.

The invention discloses a compound sanitary insecticidal composition and application thereof, the effective components are an active component A and an active component B, the active component A is oxadiazon, the active component B is a piperic acid derivative compound, and the balance is an auxiliary agent. The weight ratio of the active component A to the active component B is (1: 20)-(20: 1), preferably (1: 5)-(5: 1), and the total weight of the active component A and the active component B accounts for 2-80% of the weight of the composition. The binary composition solves the problem of resistance of sanitary pests to pyrethroids, and has the characteristics of high efficiency, low toxicity, environmental friendliness and the like. The binary composition is suitable for preventing and treating indoor and outdoor sanitary pests including mosquitoes, flies, cockroaches, fleas, bugs, diplods and the like, and is suitable for families, restaurants, hotels, carriages, animal breeding places and the like.

The invention discloses a p-Ga2O3 / n-Ga2O3pn junction diode and a preparation method thereof, and solves the problems that gallium oxide p-type doping is difficult, and a heterojunction diode is large in leakage current and low in withstand voltage. The gallium oxide homogeneous pn junction structure comprises cathode metal, a substrate and an n-type Ga2O3 epitaxial layer from bottom to top, a p-type NiO layer is arranged above the n-type Ga2O3 epitaxial layer, a p-type Ga2O3 material layer is arranged between the n-type Ga2O3 epitaxial layer and the p-type NiO layer, and a gallium oxide homogeneous pn junction is formed. The preparation method comprises the steps of epitaxial wafer cleaning, p-type Ga2O3 material layer preparation, cathode metal preparation, photoetching, p-type NiO film deposition, photoetching and anode metal preparation. N / P ion implantation is carried out on the upper portion of the gallium oxide epitaxial layer, Ga atoms in Ga2O3 are separated out and react again through high-temperature annealing to form the effective p-type characteristic, meanwhile, the effective p-type characteristic is combined with the p-type characteristic of p-type nickel oxide, p-type doping of gallium oxide is achieved through a simple process, the gallium oxide homogeneous pn junction is obtained, reliability is high, leakage current is small, and the gallium oxide homogeneous pn junction is suitable for large-scale production. The preparation method is used for preparing the p-Ga2O3 / n-Ga2O3pn junction diode with high voltage resistance.

The invention discloses an application of a small-molecule inhibitor combined medicine in preparation of a medicine for treating multiple myeloma. The application comprises the step of combining a proteasome inhibitor or an immunomodulator with an STAT3 small-molecule inhibitor. According to the present invention, the killing effect of the STAT3 targeting small molecule inhibitor BBI608 (Napabucasin) on MM cells and MM stem cells is provided, and the STAT3 targeting small molecule inhibitor BBI608 (Napabucasin) is combined with bortezomib (BTZ) or lenalidomide (Len) to improve the synergistic killing effect on multiple myeloma (MM) cells;

The invention discloses a sanitary insecticidal composition containing cyprosulfuron and propoxur and application thereof, the effective components are cyprosulfuron and propoxur, the total content of the cyprosulfuron and propoxur is 2%-70%, and the balance is an auxiliary agent; the weight ratio of the cyprosulfuron to the propoxur is (15: 1)-(1: 15); the dosage form of the sanitary insecticidal composition is a suspending agent, an oil suspending agent, a dry suspending agent, wettable powder and water dispersible granules. According to the sanitary insecticidal composition, on one hand, the environmental compatibility is good, the use amount of pesticides is reduced, on the other hand, from the aspect of the action mechanism, the action mechanisms of the cyprosulfuron and the propoxur are different, cross resistance does not exist, the control effect is improved, and the insecticide resistance of pests can be delayed by compounding the two insecticides with different action mechanisms; the resistance treatment of the pests is facilitated.

The present invention relates to a hypochlorous acid composite disinfectant and a preparation method thereof, and relates to the technical field of disinfectants. The hypochlorous acid composite disinfectant comprises the following components by weight: 60-75 parts of hypochlorous acid aqueous solution, 3-8 parts of scutellaria baicalensis extract, 19.5-25 parts of polyethylene glycol, 2-5 parts of surfactant and 0.5-2 parts of phosphate. The present invention mainly uses hypochlorous acid and introduces an appropriate proportion of scutellaria baicalensis extract as a disinfection component, which significantly enhances the overall disinfection effect of the obtained disinfectant; at the same time, other components such as polyethylene glycol and phosphate are matched, which significantly enhances the stability of the obtained disinfectant, and has efficient bactericidal performance against pathogenic microorganisms such as African swine fever virus, which can meet the sterilization and disinfection needs of farms.

The invention relates to a TCR-T cell preparation method and a TCR-T cell product. The preparation method of the TCR-T cell provided by the invention comprises a step of introducing annular mRNA (messenger Ribonucleic Acid) into a T cell modified by a non-T cell receptor gene; and, the cyclic mRNA comprises a first cyclic mRNA encoding a T cell receptor; in addition, the first annular mRNA comprises the following sequence (a) or (b): (a) a translation starting sequence and a coding sequence; and (b) translating the starting sequence, the coding sequence and the insertion element sequence. In the method, the transfection efficiency of the annular mRNA is high; compared with a virus system and the like, the process is extremely simple, and the production cost and the detection cost are greatly reduced; compared with linear mRNA, the protein expression time is greatly prolonged; compared with a virus system, a transposon system and a CRISPR system, the safety risk is greatly reduced.

The invention relates to the technical field of cell culture, and particularly provides an NK (Natural Killer) cell serum-free culture solution which is prepared from 24 percent by mass of traditional Chinese medicine extract and the balance of serum-free culture solution, the culture method of the NK cells comprises the following steps: adding the NK cells into a culture bottle, sampling and counting, diluting the cell density to 1 * 10 < 6 > / mL by using the serum-free culture solution of the NK cells, culturing in an incubator with the temperature of 37 DEG C and the CO2 content of 5% for 15 days, sampling and counting, circularly placing in a 326 mT magnetic field for 540 seconds and a 383 mT magnetic field for 120 seconds during culture, and keeping the two magnetic field environments at an interval of 0.5 hour. The serum-free culture device has a unique serum-free culture-magnetic field system, so that the multiplication capacity and killing capacity of the NK cells are not influenced or even improved while serum is not used.

The invention provides a drug delivery system combined with targeted nasopharyngeal carcinoma treatment and a preparation method and application thereof, and belongs to the technical field of biomedicine.The drug delivery system is characterized in that a liposome is modified by a nucleic acid aptamer S3 specifically targeting nasopharyngeal carcinoma cells, and then an anti-cancer drug adriamycin is entrapped for targeted killing of NPC cells and tissues; besides, NK cells modified by nucleic acid aptamers S3 and PD-L1 are prepared for targeted infiltration of NPC tissues, the NK cells modified by the nucleic acid aptamers S3 and PD-L1 are combined with anti-PD-L1 antibodies to induce'antibody-dependent cytotoxic effect ', and finally, a chemotherapeutic drug targeted delivery system and immunotherapy are organically combined to form a multi-mode therapeutic scheme. And while multi-angle and multi-layer striking is carried out on tumors, the toxic and side effects on normal cells and tissues can be reduced, and the treatment effect on nasopharyngeal carcinoma patients is remarkably improved.

The invention discloses a chimeric antigen receptor double-negative T cell drug co-expressing CXCR5 and IL-7 and application thereof, the cell drug can co-express CXCR5 and IL-7, and the cell drug comprises EF1-alpha, a CD8 alpha signal peptide, an NKG2D extracellular domain, a CD8 alpha hinge region, a CD8 alpha transmembrane region, a costimulatory factor 4-1BB, a CD3 zeta intracellular signal region, T2A, a chemotactic factor receptor CXCR5, P2A and interleukin IL-7 which are connected in sequence; according to the chimeric antigen receptor double-negative T cell drug co-expressing the CXCR5 and the IL-7 and the application of the chimeric antigen receptor double-negative T cell drug, the CXCR5 and the IL-7 are co-expressed on CAR-DNT cells of targeted NKG2DL, so that the migration and infiltration capacity of the drug to a tumor site is enhanced, the survival and proliferation capacity of the CAR-T cells is improved, the killing effect of the CAR-DNT cells on tumors is improved, and the drug has a good application prospect. The purpose of treating tumors is achieved, and allogenic treatment can be achieved.

The invention relates to a sanitary insecticide composition containing pyriproxyfen and application of the sanitary insecticide composition, and belongs to the technical field of insecticides. The invention discloses a sanitary insecticide composition containing pyriproxyfen. The sanitary insecticide composition is prepared from the following raw materials: anise oil, piperonyl butoxide, methyleugenol, matrine derivatives, cyfluthrin and pyriproxyfen. The anise oil can prevent evaporation of components of the insecticide and is matched with piperonyl butoxide, so that the pesticide effect duration of the insecticide is prolonged; methyeugenol destroys information transmission and mating of pests and has the effects of repelling, food refusal and growth inhibition at the same time, the matrine derivative enables the pests to die through food refusal activity, in addition, cyfluthrin and pyriproxyfen are matched to influence metamorphism and reproduction of the pests, and the killing power of the insecticide is further enhanced. According to the invention, the purpose of killing pests is achieved by prolonging the drug property of the insecticide and preventing and killing the pests from multiple aspects of information transmission, mating, feeding and stage growth of the pests.

The present invention provides a compound DOTA-HX2-DZ and its application, belonging to the field of biomedical technology. The present invention optimizes the molecular structure of DZ-HX2-DOTA, designs and adopts a special linker, and solves the problem of limited anti-tumor efficacy caused by the poor performance of radiolabeled drugs in the prior art, such as stability, lipid solubility and tumor retention time. The compound of the present invention can significantly reduce the risk of delabeling of radioactive metal ions in the in vivo environment, ensuring that it can stably play a role in the targeted site; the molecule has excellent lipid solubility and can more easily penetrate the cell membrane and vascular barrier, thereby improving the bioavailability of the drug, prolonging the in vivo circulation time, and prolonging the tumor retention time, thereby improving the treatment efficiency. The DZ-HX2-DOTA of the present invention has a broad spectrum of tumor targeting, and can be used for diagnosis and treatment of various types of malignant tumors.

This invention discloses a portable low-temperature plasma device based on a Laval nozzle structure and its application, belonging to the field of plasma technology application technology. Specifically, it includes (1) the construction of the device; and (2) the use of the device for fungal eradication treatment and transdermal drug delivery enhancement treatment. The beneficial effects achieved by this invention are as follows: This invention is the first to apply the Laval nozzle structure to a portable low-temperature plasma device. The results show that the device can effectively improve the plasma jet performance and active particle content, significantly improve the treatment effect of fungal infections of the skin and nails and the transdermal drug penetration efficiency, while solving the problems of large size, reliance on external power supply, and complex operation of traditional plasma devices. Therefore, using this invention for the treatment of fungal infections of the skin and nails and for enhanced transdermal drug delivery has advantages such as ease of operation, high safety, non-invasiveness, and high efficiency, and thus has potential application prospects in the field of skin disease treatment and transdermal drug delivery.

The invention provides a sensitizing camptothecin drug anti-tumor combined drug composition and application thereof, and particularly relates to application of an apigenin and camptothecin drug composition in preparation of anti-tumor drugs. A natural dietary supplement and an anti-tumor chemotherapeutic drug are creatively combined, a colorectal cancer in-vitro cell model is utilized to prove that the apigenin has the anti-tumor effect of sensitizing camptothecin drugs, the apigenin and the low-dose camptothecin drugs can activate a PI3K-AKT pathway and a dsDNA-cGAS-STING pathway, tumor immunogenic death is induced, and the apigenin has the anti-tumor effect. And the anti-tumor immune response is activated. The invention not only has the effects of reducing toxicity and enhancing efficacy on clinically applied camptothecin medicines, but also provides a new strategy for sensitizing colorectal cancer immunotherapy.

This application relates to the technical field of immunotherapy, specifically disclosing a CAR targeting human HER2, the CAR gene and its recombinant vector, CAR-M cells, their preparation methods, and applications. This application discloses a CAR targeting human HER2, comprising a leader peptide, an extracellular recognition region, a hinge region, a transmembrane region, and an intracellular signaling domain; the extracellular recognition region is a single-chain antibody binding to tumor antigens; the transmembrane region is any one of FcγRⅠ, FcγRⅡ, FcγRⅢ, FCER1G, and CD36 capable of activating macrophage phagocytic signals; the intracellular signaling domain is the P2 domain with the amino acid sequence shown in SEQ ID NO.5. This application also discloses a CAR gene targeting human HER2 and its recombinant vector. CAR-M cells prepared using the above-mentioned CAR targeting human HER2 exhibit strong phagocytic and killing abilities against target cells.

The present invention belongs to the technical field of transgenic drugs, and discloses a two-spotted spider mite feeding-related gene and its corresponding dsRNA sequence and application, wherein the two-spotted spider mite feeding-related gene is SSGP2970; the nucleotide sequence and amino acid sequence of the two-spotted spider mite SSGP2970; the present invention also includes a dsRNA sequence targeting the two-spotted spider mite SSGP2970 gene, and the sequence has a good silencing effect on the two-spotted spider mite SSGP2970 gene. Feeding the dsRNA sequence can significantly reduce the survival rate of the two-spotted spider mite. The SSGP2970 gene and the lethal dsRNA sequence provided by the present invention can be used for the development of transgenic anti-mite plants or new acaricides.

The invention discloses a biological agent capable of removing tumor cell DNA methylation and application of the biological agent. The biological preparation comprises engineered immune cells and a DNA methylated transferase inhibitor. The biological agent comprises the engineered immune cells expressing the chimeric antigen receptor and the DNA methyltransferase inhibitor, and the DNA methyltransferase inhibitor is combined with CAR-T to induce activation of a congenital immune signal channel so as to induce generation of I FN-beta and promote up-regulation of I FN-beta expression in tumor cells, so that the effect of killing the tumor cells is achieved.

The present invention relates to a drug carrier based on bacterial cell membrane and its preparation method and application. The nano drug composition of the present invention includes a drug and a bacterial cell membrane drug-carrying system, wherein the bacterial cell membrane drug-carrying system encapsulates the drug; the bacterial cell membrane drug-carrying system includes a bacterial cell membrane and a liposome; the bacterial cell membrane is wrapped outside the liposome; it can be efficiently enriched in the tumor site, release a drug that can kill Fusobacterium nucleatum, effectively alleviate the immunosuppressive microenvironment caused by Fusobacterium nucleatum, restore the response of colon cancer to anti-cytotoxic T lymphocyte-associated antigen 4 therapy and anti-programmed death receptor therapy, and can also effectively alleviate the resistance of Fusobacterium nucleatum to chemotherapy drugs, and restore the responsiveness of the tumor to the chemotherapy drug 5-fluorouracil. The nano drug composition can also kill a variety of bacteria in the breast cancer tumor site to alleviate tumor metastasis caused by tumor bacteria, and restore the responsiveness of the tumor to the combined chemotherapy regimen.

The invention relates to the technical field of cell culture. The invention provides a culture method for enhancing the secretion ability of DC-CIK cell factors, which comprises the following steps: (1) culturing colon cancer cells to obtain cultured colon cancer cells; (2) mixing the cultured colon cancer cells and DC-CIK cells, and co-culturing to obtain a co-culture product; (3) adding a BrefeldinA solution and a monensin solution into the co-culture product for blocking to obtain a blocked product; and (4) centrifuging the blocked product, re-suspending the precipitate, and sealing to obtain the DC-CIK with enhanced cytokine secretion ability. According to the invention, the DC-CIK cells with enhanced cytokine secretion ability are obtained by utilizing the stimulation effect of colon cancer cells on the DC-CIK cells and co-stimulation under specific culture conditions. The secretion capacity of cell factors is enhanced, the killing effect on tumor cells is remarkably improved, and the immune memory effect is enhanced.

The invention discloses oligopeptide and application thereof in improving proliferation activity and lethality of human natural killer cells. When the polypeptide with the sequence of RVHGLPRV provided by the invention is used for in-vitro culture of NK cells, not only can the proliferation activity of the NK cells be improved, but also the killing power of the NK cells to tumor cells can be improved. Therefore, the polypeptide can be used for in-vitro culture of NK cells.

This invention relates to the fields of brachytherapy and radiosensitization, specifically providing a... 125 I-nano implantable particles, their preparation methods, and applications. 125 The 1-nanometer implanted particles have a core-shell structure, consisting of a particle core and particles adsorbed on the outer surface of the particle core. 125 I and the particles encapsulated in the nucleus and 125 The outer shell of the I-type photosensitizer is a covalent organic framework. This invention... 125 The core of the I-nanometer implanted particle is used to enhance the energy deposition of gamma rays and X-rays, generating more hydroxyl radicals; the shell containing a type I photosensitizer is used to absorb the energy of Auger electrons and internal conversion electrons and excite the photosensitizer to generate singlet oxygen, effectively improving the response to... 125 The efficiency of I decay energy utilization. 125 I-nano implanted particles, combined with internal radiation therapy and radiodynamic therapy, destroy tumor cell DNA and cell membranes, enhance tumor killing and induce immunogenic cell death, thereby activating anti-tumor immunity and inducing remote effects.

The invention discloses application of 8-hydroxyquinoline in prevention and treatment of cyanobacterial bloom, and belongs to the technical field of environmental protection. The method comprises the following steps: 1) dissolving 8-hydroxyquinoline in dimethyl sulfoxide to prepare a solution with the concentration of 0.8-1mM; and 2) adding the 8-hydroxyquinoline solution prepared in the step 1) into a water body with blue-green algae outbreak according to a volume ratio of 0.1% (final concentration of 0.8-1 [mu] M), wherein the algae are subjected to mass death. 8-hydroxyquinoline has a remarkable killing effect on water-blooming cyanobacteria, and the removal rate of 0.9 mu M of 8-hydroxyquinoline on severe cyanobacterial blooms (the algae density is about 5 * 10 < 8 > cells / L) reaches 100%. 8-hydroxyquinoline has a destructive effect on a photosynthetic system of blue-green algae.

The present application belongs to the field of disease treatment and immunology, in particular, the present application discloses an antibody or antigen-binding fragment thereof against CD73, a nucleic acid molecule encoding the same, an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the same, and the use thereof for enhancing an immune response and / or treating a tumor.